Morinda Officinalis Oligosaccharides Alleviate Post-Stroke Depression-Like Behaviors Alongside Increased Gut Microbial Diversity and Butyrate Levels and Reduced Hippocampal Pla2g4a Expression.

Authors

Hui Ma, Yue Chen, Xinzhou Deng, Xuan Fang, Wenhui Xiao, Qian Long, Lu Du, Fuze Du, Haonan Chen, Yan Wang, Bo Gao, Xin Qiao

Published in

CNS neuroscience & therapeutics. Volume 32. Issue 11.

Abstract

Post-stroke depression (PSD) represents a common and debilitating complication after cerebral ischemia, yet mechanism-based therapies remain an urgent unmet need. The microbiota-gut-brain axis has been implicated in PSD pathophysiology, but the precise molecular pathways are largely elusive. Morinda officinalis oligosaccharides (MOO), a clinically approved antidepressant in China, exhibit poor oral absorption, raising the possibility of a gut-dependent mechanism.
Male C57BL/6J mice were subjected to transient middle cerebral artery occlusion (MCAO) followed by 21 days of chronic restraint stress (CRS) to establish a PSD model. MOO (50 mg/kg/day) was administered via gavage from Day 7 to 27. Depression-like behaviors, 16S rRNA-based gut microbiota profiling, short-chain fatty acid (SCFA) quantification, intestinal and blood-brain barrier integrity assessments, and hippocampal proteomics were performed. The transferability of MOO-associated fecal effects was assessed using a donor-controlled fecal microbiota transplantation (FMT) design. The butyrate-Pla2g4a relationship was further examined by sodium butyrate supplementation and AAV-mediated hippocampal Pla2g4a overexpression.
MOO administration altered gut microbial composition, increased the abundance of probiotics and decreased the abundance of harmful bacteria, and was accompanied by increased fecal butyrate levels. The donor-controlled FMT experiment provided preliminary evidence that fecally transferable factors from MOO-treated PSD donors may contribute to behavioral improvements in PSD recipients. MOO and sodium butyrate treatment were associated with improved indices of intestinal and blood-brain barrier integrity. Hippocampal proteomics identified Pla2g4a, a phospholipase linked to neuroinflammation, as a candidate molecule related to the observed effects. Both MOO and sodium butyrate treatment were associated with reduced hippocampal Pla2g4a expression, and Pla2g4a expression was inversely correlated with butyrate levels. Hippocampal Pla2g4a overexpression attenuated the behavioral improvements associated with sodium butyrate treatment, supporting the functional involvement of Pla2g4a in the response to sodium butyrate.
MOO treatment was associated with improved depression-like behaviors in PSD mice, accompanied by gut microbial alterations, increased fecal butyrate, improved barrier integrity, and reduced hippocampal Pla2g4a expression. FMT findings provided preliminary evidence that fecally transferable factors from MOO-treated donors may contribute to behavioral improvements, while Pla2g4a overexpression attenuated the behavioral effects of sodium butyrate. These findings highlight a potential association among MOO, gut-derived butyrate, barrier integrity, and hippocampal Pla2g4a in PSD.

PMID:
42958990
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.